Integra Lifesciences Holdings (IART) Touches $54.85 High on Jul, 17, Cannell Capital Has Trimmed Its Biotelemetry (BEAT) Holding

July 17, 2017 - By Richard Conner

Cannell Capital Llc decreased Biotelemetry Inc (BEAT) stake by 6.67% reported in 2016Q4 SEC filing. Cannell Capital Llc sold 65,404 shares as Biotelemetry Inc (BEAT)’s stock rose 13.43%. The Cannell Capital Llc holds 915,560 shares with $20.46 million value, down from 980,964 last quarter. Biotelemetry Inc now has $985.74M valuation. The stock declined 0.58% or $0.2 reaching $34.2 per share. About 430,007 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 87.79% since July 17, 2016 and is uptrending. It has outperformed by 71.09% the S&P500.

The stock of Integra Lifesciences Holdings Corp (NASDAQ:IART) reached all time high today, Jul, 17 and still has $56.50 target or 3.00% above today’s $54.85 share price. This indicates more upside for the $4.19B company. This technical setup was reported by Barchart.com. If the $56.50 PT is reached, the company will be worth $125.70 million more. About 102,159 shares traded. Integra Lifesciences Holdings Corp (NASDAQ:IART) has risen 32.67% since July 17, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on August, 1. They expect $0.21 EPS, up 5.00% or $0.01 from last year’s $0.2 per share. BEAT’s profit will be $6.05 million for 40.71 P/E if the $0.21 EPS becomes a reality. After $0.16 actual EPS reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts 31.25% EPS growth.

Investors sentiment decreased to 1.03 in Q4 2016. Its down 0.36, from 1.39 in 2016Q3. It is negative, as 24 investors sold BEAT shares while 52 reduced holdings. 26 funds opened positions while 52 raised stakes. 22.34 million shares or 1.83% less from 22.76 million shares in 2016Q3 were reported. Comerica National Bank & Trust owns 29,803 shares. Da Davidson And Company invested 0% in BioTelemetry, Inc. (NASDAQ:BEAT). Manufacturers Life Insur The holds 0% or 18,654 shares in its portfolio. Ny State Common Retirement Fund has invested 0.01% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT). Piermont Cap Management Inc has 28,590 shares for 0.15% of their portfolio. Morgan Stanley stated it has 150,846 shares or 0% of all its holdings. American holds 19,972 shares. Moreover, Principal Gru Inc Inc has 0.01% invested in BioTelemetry, Inc. (NASDAQ:BEAT). Teachers Retirement Of The State Of Kentucky owns 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 14,500 shares. Sei Investments Company reported 1,007 shares stake. Avalon Advsrs Limited accumulated 31,099 shares or 0.03% of the stock. Acadian Asset Mngmt Lc holds 0.06% or 567,591 shares. Argent Capital Mngmt Ltd Liability Com holds 0.16% of its portfolio in BioTelemetry, Inc. (NASDAQ:BEAT) for 175,657 shares. Moreover, Schwab Charles Invest Mgmt has 0% invested in BioTelemetry, Inc. (NASDAQ:BEAT) for 118,630 shares. 300 are owned by Creative Planning.

Among 3 analysts covering BioTelemetry (NASDAQ:BEAT), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. BioTelemetry had 5 analyst reports since July 28, 2015 according to SRatingsIntel. Dougherty & Company initiated the shares of BEAT in report on Friday, December 2 with “Buy” rating. Dougherty & Company maintained the stock with “Buy” rating in Tuesday, July 28 report. The firm earned “Buy” rating on Tuesday, September 13 by Sidoti. The rating was maintained by Dougherty & Company on Tuesday, April 11 with “Buy”.

Analysts await Integra Lifesciences Holdings Corp (NASDAQ:IART) to report earnings on July, 26 before the open. They expect $0.44 earnings per share, up 10.00% or $0.04 from last year’s $0.4 per share. IART’s profit will be $33.61M for 31.16 P/E if the $0.44 EPS becomes a reality. After $0.39 actual earnings per share reported by Integra Lifesciences Holdings Corp for the previous quarter, Wall Street now forecasts 12.82% EPS growth.

Integra LifeSciences Holdings Corporation is a medical technology company. The company has market cap of $4.19 billion. The Firm focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. It has a 65.01 P/E ratio. The Company’s divisions include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Among 12 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Integra Lifesciences Holdings Corp. had 19 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Buy” rating by Bank of America on Monday, September 21. The firm has “Hold” rating by Lake Street given on Thursday, April 28. RBC Capital Markets maintained it with “Sector Perform” rating and $46 target in Friday, January 13 report. Zacks downgraded the shares of IART in report on Monday, August 24 to “Hold” rating. Raymond James upgraded the stock to “Outperform” rating in Wednesday, July 29 report. Lake Street upgraded the shares of IART in report on Friday, October 28 to “Buy” rating. Jefferies maintained the stock with “Buy” rating in Tuesday, May 30 report. Cantor Fitzgerald maintained it with “Buy” rating and $6500 target in Sunday, July 9 report. On Monday, August 3 the stock rating was upgraded by JP Morgan to “Overweight”. The firm has “Overweight” rating given on Wednesday, July 13 by JP Morgan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: